243 related articles for article (PubMed ID: 36046790)
1. A retrospective, matched case-control study of recombinant LH versus hMG supplementation on FSH during controlled ovarian hyperstimulation in the GnRH-antagonist protocol.
Chen MJ; Yi YC; Guu HF; Chen YF; Kung HF; Chang JC; Chuan ST; Chen LY
Front Endocrinol (Lausanne); 2022; 13():931756. PubMed ID: 36046790
[TBL] [Abstract][Full Text] [Related]
2. A direct healthcare cost analysis of recombinant LH versus hMG supplementation on FSH during controlled ovarian hyperstimulation in the GnRH-antagonist protocol.
Chang JC; Yi YC; Chen YF; Guu HF; Kung HF; Chen LY; Chuan ST; Chang YM; Chen MJ
Arch Gynecol Obstet; 2024 Feb; 309(2):699-706. PubMed ID: 38099955
[TBL] [Abstract][Full Text] [Related]
3. Recombinant LH supplementation improves cumulative live birth rates in the GnRH antagonist protocol: a multicenter retrospective study using a propensity score-matching analysis.
Wang M; Huang R; Liang X; Mao Y; Shi W; Li Q
Reprod Biol Endocrinol; 2022 Aug; 20(1):114. PubMed ID: 35941630
[TBL] [Abstract][Full Text] [Related]
4. Supplementation with human menopausal gonadotropin in the gonadotropin-releasing hormone antagonist cycles of women with high AMH: Pregnancy outcomes and serial hormone levels.
Chen LH; Chin TH; Huang SY; Yu HT; Chang CL; Huang HY; Wang HS; Soong YK; Wu HM
Taiwan J Obstet Gynecol; 2021 Jul; 60(4):739-744. PubMed ID: 34247817
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders.
Humaidan P; Chin W; Rogoff D; D'Hooghe T; Longobardi S; Hubbard J; Schertz J;
Hum Reprod; 2017 Mar; 32(3):544-555. PubMed ID: 28137754
[TBL] [Abstract][Full Text] [Related]
6. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
Vuong TN; Phung HT; Ho MT
Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
[TBL] [Abstract][Full Text] [Related]
7. LH on GnRH-ant day to basal LH affects the IVF/ICSI outcome of PCOS women undergoing GnRH-antagonist protocol.
Wei Y; Luan T; Shen J; Zhang J; Zhang J; Su Y; Ling X; Li X; Zhao C
Int J Gynaecol Obstet; 2024 Feb; 164(2):624-632. PubMed ID: 37724009
[TBL] [Abstract][Full Text] [Related]
8. Dosing Characteristics of Recombinant Human Luteinizing Hormone or Human Menopausal Gonadotrophin-Derived LH Activity in Patients Undergoing Ovarian Stimulation: A German Fertility Database Study.
Strezsak V; Allignol A; Bühler K; Fischer R; Hubbard J; Longobardi S; Lispi M; Schertz J; Verpillat P
Gynecol Obstet Invest; 2023; 88(4):214-225. PubMed ID: 37369184
[TBL] [Abstract][Full Text] [Related]
9. Recombinant human LH supplementation versus supplementation with urinary hCG-based LH activity during controlled ovarian stimulation in the long GnRH-agonist protocol: a matched case-control study.
Bühler KF; Fischer R
Gynecol Endocrinol; 2012 May; 28(5):345-50. PubMed ID: 22115012
[TBL] [Abstract][Full Text] [Related]
10. The Utrogestan and hMG protocol in patients with polycystic ovarian syndrome undergoing controlled ovarian hyperstimulation during IVF/ICSI treatments.
Zhu X; Ye H; Fu Y
Medicine (Baltimore); 2016 Jul; 95(28):e4193. PubMed ID: 27428219
[TBL] [Abstract][Full Text] [Related]
11. The impact of adding hp-hMG in r-FSH started GnRH antagonist cycles on ART outcome.
Kan O; Simsir C; Atabekoglu CS; Sonmezer M
Gynecol Endocrinol; 2019 Oct; 35(10):869-872. PubMed ID: 30973022
[TBL] [Abstract][Full Text] [Related]
12. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
[TBL] [Abstract][Full Text] [Related]
13. Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles.
Mochtar MH; Danhof NA; Ayeleke RO; Van der Veen F; van Wely M
Cochrane Database Syst Rev; 2017 May; 5(5):CD005070. PubMed ID: 28537052
[TBL] [Abstract][Full Text] [Related]
14. Controlled Ovarian Stimulation Using Medroxyprogesterone Acetate and hMG in Patients With Polycystic Ovary Syndrome Treated for IVF: A Double-Blind Randomized Crossover Clinical Trial.
Wang Y; Chen Q; Wang N; Chen H; Lyu Q; Kuang Y
Medicine (Baltimore); 2016 Mar; 95(9):e2939. PubMed ID: 26945402
[TBL] [Abstract][Full Text] [Related]
15. [Timing of HMG supplementation and clinical outcomes of advanced-age patients with diminished ovarian reserve receiving gonadotropin-releasing hormone antagonist protocol].
Wu X; Chen Y; Zhou X; Zhang J; Li Y; Li X; Zhang X; Chen S
Nan Fang Yi Ke Da Xue Xue Bao; 2021 Mar; 41(3):412-417. PubMed ID: 33849833
[TBL] [Abstract][Full Text] [Related]
16. A double-blind, randomized study to compare recombinant human follicle stimulating hormone (FSH; Gonal-F) with highly purified urinary FSH (Metrodin) HP) in women undergoing assisted reproductive techniques including intracytoplasmic sperm injection. The French Multicentre Trialists.
Frydman R; Howles CM; Truong F
Hum Reprod; 2000 Mar; 15(3):520-5. PubMed ID: 10686190
[TBL] [Abstract][Full Text] [Related]
17. Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic sperm injection treatments in combination with embryo cryopreservation.
Zhu X; Ye H; Fu Y
Fertil Steril; 2017 Sep; 108(3):505-512.e2. PubMed ID: 28697910
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of recombinant human FSH: recombinant human LH combination treatment versus recombinant human FSH alone for assisted reproductive technology in women aged 35-40 years.
Bielfeld AP; Schwarze JE; Verpillat P; Lispi M; Fischer R; Hayward B; Chuderland D; D'Hooghe T; Krussel JS
Reprod Biomed Online; 2024 Jun; 48(6):103725. PubMed ID: 38593745
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human follicle-stimulating hormone (r-hFSH) plus recombinant luteinizing hormone versus r-hFSH alone for ovarian stimulation during assisted reproductive technology: systematic review and meta-analysis.
Lehert P; Kolibianakis EM; Venetis CA; Schertz J; Saunders H; Arriagada P; Copt S; Tarlatzis B
Reprod Biol Endocrinol; 2014 Feb; 12():17. PubMed ID: 24555766
[TBL] [Abstract][Full Text] [Related]
20. A premature luteinizing hormone surge without elevated progesterone levels has no adverse effect on cumulative live birth rate in patient undergoing a flexible GnRH antagonist protocol: a retrospective study.
Zhang Y; Xu Y; Yu J; Wang X; Xue Q; Shang J; Yang X; Shan X
J Ovarian Res; 2023 Jun; 16(1):119. PubMed ID: 37370146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
